Barclays initiated coverage of Phreesia (PHR) with an Overweight rating and $26 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia reports Q3 adjusted EBITDA $29.1M vs. $9.8M last year
- Phreesia raises FY26 revenue view to $479M-$481M from $472M-$482M
- Phreesia sees FY27 revenue $545M-$559M, consensus $569.5M
- Options Volatility and Implied Earnings Moves Today, December 08, 2025
- Phreesia’s Strategic Growth and Financial Performance Drive Buy Rating Amid Attractive Valuation